Humira approved for AS in Europe

European regulators have now given Abbott Labs permission to market Humira (adalimumab) as a treatment for ankylosing spondylitis: Business Week; TradingMarkets.com. The FDA is still reviewing the application in the U.S.

See previous entries: Adalimumab (Humira) and ankylosing spondylitis; More about adalimumab; Humira recommended for AS in Europe.

Update, June 8: Chicago Tribune.